Provides an algorithm for anticoagulant deprescribing in post-discharge COVID-19 patients, emphasizing continued prophylaxis for those with high thromboembolic and low bleeding risks.
Answers are grounded in this paper and cite their sources.
Supports risk-stratified continuation of post-discharge anticoagulation in COVID-19; extends guidelines into the recovery period.
We present anticoagulant outpatient deprescribing algorithm in patients with COVID-19 discharged from the hospital. It is reasonable to continue the treatment should the patient have indications for therapeutic anticoagulation. Enhanced prophylaxis of venous thromboembolic complications should be considered in patients with high thromboembolic risk and low risk of bleeding.
No takes yet. Share an insight, caveat, or question.
Krykov et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: